Heterotopic ossification (HO), the formation of ectopic endochondral bone in skeletal muscle and soft tissues, is a significant cause of morbidity from joint immobility and pain. The precise mechanisms responsible for HO remain incompletely understood; however, the association with genetic gain-of- function syndromes affecting receptors and ligands of the bone morphogenetic protein (BMP) and activin signaling pathways has generated important insights and translatable strategies. We have previously identified activin A as the dominant ligand responsible for the congenital HO syndrome fibrodysplasia ossificans progressiva (FOP), being transduced via mutant ACVR1 encoding ALK2. In subsequent work using a ligand trap, we and collaborators found that ligands of the BMP type I receptor ALK3 account for a major portion of non-genetic forms of HO, frequently complicating joint replacement surgeries, burn injuries, blast trauma, or inflammatory arthropathies. In the parent grant for this supplement we describe several pharmacologic and genetic strategies for narrowing the identify of ligands and receptors responsible for non-genetic forms of HO, using genetically modified human derived tissue cultures and genetically modified mouse reagents and tissues. Here we propose to generate a panel of novel reagents that can selectively target signaling via specific type I and type II receptors in this pathway in non-transfected or non-engineered tissues, and thus permit complementary studies in unmodified human and rodent tissues without artifacts due to genetic modification or off-target effects confounding interpretation. Moreover, these antibody-based reagents would have pharmacokinetics suitable for in vivo validation studies and could be rapidly translated into therapies for tissue regeneration or orthopedic applications. Importantly. these studies will provide a robust set of tools that can be used to further elucidate the molecular blueprint for development, wound healing, as well as HO involving skeletal muscle and tendon niches, and create a broad platform for scientific discovery and translational work in musculoskeletal disease.

Public Health Relevance

The bone morphogenetic protein (BMP) and transforming growth factor b (TGFb) are potent regulators of normal bone development as well as inappropriate (heterotopic) bone formation. The naturally occurring ligands of this pathway are promiscuous in their binding with multiple receptors, and have poor pharmacokinetics, limiting their utility as probes of function or as potential drug molecules. This proposal develops novel reagents that can initiate or modulate signaling of BMP and TGFb with high specificity and potency, and may thus be able to target intended tissues with greater selectivity, and with the potential for rapid translation as therapeutic molecules.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
3R01AR057374-07S1
Application #
10051129
Study Section
Program Officer
Chen, Faye H
Project Start
2019-07-01
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Alessi Wolken, Dana M; Idone, Vincent; Hatsell, Sarah J et al. (2018) The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone 109:210-217
Jiang, Jian-Kang; Huang, Xiuli; Shamim, Khalida et al. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett 28:3356-3362
Dey, Devaveena; Wheatley, Benjamin M; Cholok, David et al. (2017) The traumatic bone: trauma-induced heterotopic ossification. Transl Res 186:95-111
Agarwal, Shailesh; Loder, Shawn J; Breuler, Christopher et al. (2017) Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification. Mol Ther 25:1974-1987
Nikolic, Ivana; Yu, Paul B (2016) The Role of Bone Marrow-derived Cells in Pulmonary Arterial Hypertension. What Lies Beneath? Am J Respir Crit Care Med 193:822-4
Morrell, Nicholas W; Bloch, Donald B; ten Dijke, Peter et al. (2016) Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol 13:106-20
O'Rourke, Caitlin; Shelton, Georgia; Hutcheson, Joshua D et al. (2016) Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation. J Vis Exp :
Dey, Devaveena; Bagarova, Jana; Hatsell, Sarah J et al. (2016) Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci Transl Med 8:366ra163
Chun, Hyung J; Yu, Paul B (2015) Elafin in pulmonary arterial hypertension. Beyond targeting elastases. Am J Respir Crit Care Med 191:1217-9
Hatsell, Sarah J; Idone, Vincent; Wolken, Dana M Alessi et al. (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med 7:303ra137

Showing the most recent 10 out of 31 publications